In this issue, read about immunostimulation from chemotherapeutic agents, cancer in older adults, ctDNA applications in colorectal cancer and artificial intelligence in radiotherapy.

In this issue, read about photothermal and photodynamic therapies for cancer, integrating evolutionary dynamics in cancer therapy, early detection and prevention of breast cancer, and immunotherapy discontinuation.

In this issue, read about simultaneous drug approvals in China and the USA, SABR in oligometastatic disease, the adenosine pathway in cancer, the tumour antigenic repertoire, and cancer epidemiology in the USA.

In this issue, read about cancer screening with liquid biopsies, the pancreatic tumour microenvironment, cancer of unknown primary, MET alterations in cancer, and histology-agnostic drug development.

In this issue, read about alternative splicing in cancer, the biology of allogeneic HSCT, treatment-free remission in patients with CML, and treatment of immune-related adverse events.

In this issue, read about therapeutic targeting of apoptosis, T cell-engaging therapies, and the SWI/SNF complex in cancer.

In this issue, read about tissue-resident memory T cells, folate receptor signalling, lineage plasticity and prostate cancer diagnosis.

In this issue, read about management of brain metastases, and immunotherapy for small-cell lung cancer and during the perioperative period.

In this issue, read about stem cell-related signalling pathways in cancer, early stage HER2-positive breast cancer and nanomedicine-based immunotherapy approaches.

In this issue, read about oncology drug approvals, novel CAR T cell strategies, cytoreductive strategies for prostate cancer and deep phenotyping.

In this issue, read about epigenetic therapies in oncology and novel agents for advanced-stage pancreatic cancer.

In this issue, read about biomarkers in colorectal cancer, targeting HER2 beyond breast cancer and oncolysis without viruses.